Latus Bio at ESGCT 2026
Oct 27–30, 2026 Hamburg, Germany ~2.5k attendees Website
Latus Bio brings 4 presentations to ESGCT 2026 in Hamburg. Its work centres on engineered AAV capsids matched to the route of delivery, with programmes in CLN2 Batten disease and a Huntington's therapy that lowers MSH3. Other capsids are aimed at neurons across the brain and spinal cord and at the kidney.
| Organization | ESGCT 2026 Attendance |
|---|---|
Latus Bio Philadelphia, PA | |
Develops AAV gene therapies using engineered capsids and tailored routes of delivery, with programs in CLN2 Batten disease and Huntington's disease. | Poster Wed Oct 28 1:30pm–3:30pm LTS-101: An Intracerebroventricular Delivered AAV Gene Therapy Using a Novel Capsid Variant for the Treatment of CLN2 Batten Disease Poster Thu Oct 29 2:00pm–4:00pm Computational Modeling and Preclinical Evidence Supporting LTS-201, an MSH3-Lowering Therapy for Huntington’s Disease Poster Thu Oct 29 2:00pm–4:00pm Engineering Novel Kidney-tropic AAV Capsids for Enhanced Gene Therapy in Renal Disease Poster Thu Oct 29 2:00pm–4:00pm Neuronal-tropic AAV capsid variants for efficient brain and spinal cord transduction after direct CNS delivery |
Instantly find 20 buyers from Latus Bio
Get a list of who you should contact, their contact info, and what to say.
Totally free and instant, no sign up necessary!
Not affiliated with or endorsed by the European Society of Gene & Cell Therapy. Submit a correction